EUROPEAN ACADEMY OF NEUROLOGY

Due to the COVID-19 pandemic, the 7th EAN Congress was a Virtual Congress. This site enables you to access the presentations that were presented at the EAN virtual meeting.

Due to the COVID-19 pandemic, the 6th EAN Congress was a Virtual Congress. This site enables you to access the presentations that were presented at the EAN virtual meeting.

The presentations downloaded using this platform are intended as an educational resource for legitimate scientific exchange and not for promotional use.

June 19–22 | Virtual

May 23 - 26 2020 | Paris

EUROPEAN ACADEMY OF NEUROLOGY

View the list of presentations

Consistent efficacy and safety of erenumab in episodic migraine patients during a 5-year, open-label extension study

Ashina M, et al; Oral presentation: OPR-136

Erenumab versus topiramate for the prevention of migraine: results of a randomized active-controlled double-dummy trial (HER-MES)

Uwe Reuter, et al; Oral presentation: OPR-200

Migraine-related healthcare resource utilisation and costs associated with migraine chronification: a panel-based chart review

Vo P, et al; ePresentation: EPR-152

The SQUARE study population: patient characteristics of erenumab-treated patients in a real-world setting in Switzerland

Schäfer E, et al. ePoster: EPO-264

Cost offsets for erenumab responders regarding migraine-related healthcare resource use and productivity loss in Portugal

Silva C, et al; ePoster: EPO-274

Efficacy and safety of erenumab in Indian episodic migraine population: India subanalysis of Global EMPOwER study

Chowdhury D, et al; ePoster: EPO-420

The effect of erenumab on sick leave days and healthcare visits in patients with migraine in Finland

Nissilä M, et al; ePoster: EPO-732

Impact of erenumab in a Scandinavian chronic migraine population – an interim analysis of the IMPROVE phase IV trial

Amin FM et al; ePoster: EPO-735
MLR ID: 134909

Cardiovascular safety of erenumab in patients with migraine with or without a history of aura

Ashina, M. (2020). Cardiovascular safety of erenumab in patients with migraine with or without a history of aura. European Journal of Neurology, 27 (Suppl. 1), 1–102. Pg. 12
Oral presentation: O1016

Characteristics of the first head-to-head randomized, double-blind, double-dummy trial of erenumab and topiramate for the prevention of episodic and chronic migraine

Ehrlich, M. (2020). Characteristics of the first head-to-head, randomized, double-blind, double-dummy trial of erenumab and topiramate for the prevention of episodic and chronic migraine. European Journal of Neurology, 27 (Suppl. 1), 1–102. Pg. 13
Oral presentation: O1017

Characterisation of prescription patterns in episodic and chronic migraine patients starting treatment in a real life setting with erenumab in Germany (SPECTRE) – A Real world evidence study

Gaul, C. (2020). Characterisation of prescription patterns in episodic and chronic migraine patients starting treatment in a real life setting with erenumab in Germany (SPECTRE) – A Real world evidence study. European Journal of Neurology, 27 (Suppl. 1), 1–102. Pg. 154
ePresentation: EPR1088

Real-world trends in characteristics of migraine patients newly initiated on erenumab in the United States

Fang, J. (2020). Real-world Trends in Characteristics of Migraine Patients Newly Initiated on Erenumab in the United States. European Journal of Neurology, 27 (Suppl. 1), 1–102. Pg. 159
ePresentation: EPR1098

First data collection on the use of prophylactic migraine treatments including the monoclonal antibody erenumab focused on the patient’s personal experience (PERISCOPE)

Gaul, C. (2020). First data collection on the use of prophylactic migraine treatments including the monoclonal antibody Erenumab focused on the patient’s personal experience. European Journal of Neurology, 27 (Suppl. 1), 1–102. Pg. 161
ePresentation: EPR1101

The importance of considering the patient’s and treating physician’s view to generate comprehensive and unbiased real-world evidence data (PERISCOPE AND TELESCOPE)

Schuh, K. (2020). The importance of considering the patient’s and treating physician’s view to generate comprehensive and unbiased real-world evidence data. European Journal of Neurology, 27 (Suppl. 1), 1–102. Pg. 296
ePresentation: EPR2067

Analysis of the patient population for the assessment of long-term safety and tolerability of the monoclonal antibody erenumab and the frequency of drug holidays in the German treatment algorithm (APOLLON)

Göbel, H. (2020). Analysis of the patient population for the assessment of long-term safety and tolerability of the monoclonal antibody Erenumab and the frequency of drug holidays in the German treatment algorithm. European Journal of Neurology, 27 (Suppl. 1), 1–102. Pg. 296
ePresentation: EPR2068

Patient-reported outcomes in patients with migraine and prior prophylactic treatment failure: A subgroup analysis from the BECOME study

Pozo-Rosich, P. (2020). Patient-Reported Outcomes in Patients with Migraine and Prior Prophylactic Treatment Failure: A Subgroup Analysis from the BECOME Study. European Journal of Neurology, 27 (Suppl. 1), 1–102. Pg. 304
ePresentation: EPR2081

Impact of an employer-provided migraine coaching program on patient burden and engagement

Schaetz, L. (2020). Impact of an Employer-Provided Migraine Coaching Program on Patient Burden and Engagement. European Journal of Neurology, 27 (Suppl. 1), 1–102. Pg. 306
ePresentation: EPR2083

The burden of migraine in the Netherlands: results from the My Migraine Voice survey

Mos, E. (2020). The burden of migraine in the Netherlands: results from the My Migraine Voice Survey. European Journal of Neurology, 27 (Suppl. 1), 1–102. Pg. 866
ePoster: EPO2164

Real-world evidence data characterising the use of the monoclonal antibody erenumab in daily clinical routine in Germany from the treating physician’s perspective (TELESCOPE)

Koch, M. (2020). Real-world evidence data characterizing the use of the monoclonal antibody Erenumab in daily clinical routine in Germany from the treating physician’s perspective. European Journal of Neurology, 27 (Suppl. 1), 1–102. Pg. 442
ePresentation: EPR3045

Changes in acute migraine-specific medications after initiating erenumab: Results from a real-world retrospective cohort study in the United States

Hines, D. (2020). Changes in Acute Migraine-Specific Medications after Initiating Erenumab: Results from a Real-World Retrospective Cohort Study in the United States. European Journal of Neurology, 27 (Suppl. 1), 1–102. Pg. 443
ePresentation: EPR3047

Benefit of migraine prevention with erenumab in patients receiving background standard-of-care acute treatment

Starling, A.J. (2020). Benefit of Migraine Prevention with Erenumab in Patients Receiving Background Standard-of-Care Acute Treatment. European Journal of Neurology, 27 (Suppl. 1), 1–102. Pg. 446
ePresentation: EPR3052

Sustained efficacy and safety of erenumab in episodic migraine patients failing 2–4 prior preventive treatments: 2-Year interim results of the LIBERTY open-label extension study

Reuter, U. (2020). Sustained efficacy and safety of erenumab in episodic migraine patients failing 2–4 prior preventive treatments: 2-year in-terim results of the LIBERTY open-label extension study. European Journal of Neurology, 27 (Suppl. 1), 1–102. Pg. 1298
ePoster: EPO5039
Erenumab is co-developed by Novartis and Amgen
Cookie Settings
© Copyright 2021 Novartis Pharma AG